TY - JOUR
T1 - RNA-based therapies
T2 - A cog in the wheel of lung cancer defense
AU - Khan, Parvez
AU - Siddiqui, Jawed Akhtar
AU - Lakshmanan, Imayavaramban
AU - Ganti, Apar Kishor
AU - Salgia, Ravi
AU - Jain, Maneesh
AU - Batra, Surinder Kumar
AU - Nasser, Mohd Wasim
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Lung cancer (LC) is a heterogeneous disease consisting mainly of two subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and remains the leading cause of death worldwide. Despite recent advances in therapies, the overall 5-year survival rate of LC remains less than 20%. The efficacy of current therapeutic approaches is compromised by inherent or acquired drug-resistance and severe off-target effects. Therefore, the identification and development of innovative and effective therapeutic approaches are critically desired for LC. The development of RNA-mediated gene inhibition technologies was a turning point in the field of RNA biology. The critical regulatory role of different RNAs in multiple cancer pathways makes them a rich source of targets and innovative tools for developing anticancer therapies. The identification of antisense sequences, short interfering RNAs (siRNAs), microRNAs (miRNAs or miRs), anti-miRs, and mRNA-based platforms holds great promise in preclinical and early clinical evaluation against LC. In the last decade, RNA-based therapies have substantially expanded and tested in clinical trials for multiple malignancies, including LC. This article describes the current understanding of various aspects of RNA-based therapeutics, including modern platforms, modifications, and combinations with chemo-/immunotherapies that have translational potential for LC therapies.
AB - Lung cancer (LC) is a heterogeneous disease consisting mainly of two subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and remains the leading cause of death worldwide. Despite recent advances in therapies, the overall 5-year survival rate of LC remains less than 20%. The efficacy of current therapeutic approaches is compromised by inherent or acquired drug-resistance and severe off-target effects. Therefore, the identification and development of innovative and effective therapeutic approaches are critically desired for LC. The development of RNA-mediated gene inhibition technologies was a turning point in the field of RNA biology. The critical regulatory role of different RNAs in multiple cancer pathways makes them a rich source of targets and innovative tools for developing anticancer therapies. The identification of antisense sequences, short interfering RNAs (siRNAs), microRNAs (miRNAs or miRs), anti-miRs, and mRNA-based platforms holds great promise in preclinical and early clinical evaluation against LC. In the last decade, RNA-based therapies have substantially expanded and tested in clinical trials for multiple malignancies, including LC. This article describes the current understanding of various aspects of RNA-based therapeutics, including modern platforms, modifications, and combinations with chemo-/immunotherapies that have translational potential for LC therapies.
KW - Antisense oligonucleotides
KW - Lung cancer
KW - RNA interference
KW - anti-miRs
KW - mRNA-vaccine
UR - http://www.scopus.com/inward/record.url?scp=85102925116&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102925116&partnerID=8YFLogxK
U2 - 10.1186/s12943-021-01338-2
DO - 10.1186/s12943-021-01338-2
M3 - Review article
C2 - 33740988
AN - SCOPUS:85102925116
SN - 1476-4598
VL - 20
JO - Molecular cancer
JF - Molecular cancer
IS - 1
M1 - 54
ER -